Today, Capricor Therapeutics shared an important update on the FDA’s review of the Biologics License Application (BLA) for Deramiocel, the company’s cell therapy for the treatment of Duchenne muscular dystrophy-associated cardiomyopathy. Capricor has indicated that... The post Update on the FDA’s Review of Deramiocel: Continuing the Path Forward appeared first on Parent Project Muscular Dystrophy .
Update on the FDA’s Review of Deramiocel: Continuing the Path Forward
Parent Project Muscular Dystrophy